

S 2699

Elimination of Neglected Diseases Act of 2006

Congress: 109 (2005–2007, Ended)

Chamber: Senate

Policy Area: Commerce

Introduced: May 2, 2006

Current Status: Read twice and referred to the Committee on the Judiciary.

Latest Action: Read twice and referred to the Committee on the Judiciary. (May 2, 2006)

Official Text: <https://www.congress.gov/bill/109th-congress/senate-bill/2699>

Sponsor

Name: Sen. Brownback, Sam [R-KS]

Party: Republican • **State:** KS • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Lieberman, Joseph I. [D-CT]	D · CT		May 2, 2006

Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	Senate	Referred To	May 2, 2006

Subjects & Policy Tags

Policy Area:

Commerce

Related Bills

No related bills are listed.

Elimination of Neglected Diseases Act of 2006 - Provides for the extension and restoration of the patent term for a certified tropical disease product: (1) that is used to treat neglected or tropical diseases such as HIV, malaria, tuberculosis, or other infectious disease that disproportionately affect poor and marginalized populations; and (2) the patent for which claims an approved new molecular entity standard review drug or the process of making such a drug or the drug's active ingredient.

Requires the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to: (1) designate as a new molecular entity standard review drug a drug that has a new molecular entity chemical type classification and standard review drug treatment potential classifications and is not a drug developed to treat serious or life-threatening diseases; and (2) maintain and annually update a classification list of serious and life-threatening diseases. Allows the Secretary, acting through the Commissioner, to remove the designation of a drug as a new molecular entity standard review drug.

Requires the Director of the United States Patent and Trademark Office (USPTO) to study the effect of patent extension and restoration on the ability of pharmaceutical companies to develop and distribute tropical disease products for poor and marginalized populations.

Actions Timeline

- **May 2, 2006:** Introduced in Senate
- **May 2, 2006:** Sponsor introductory remarks on measure. (CR S3900)
- **May 2, 2006:** Read twice and referred to the Committee on the Judiciary.